tetanusan 24% šķīdums injekcijām
kon-pharma gmbh, vācija - kalcija glikonāts, magnija hlorīda heksahidrāts, kalcija glicerofosfāts - šķīdums injekcijām - cūkas; liellopi; zirgi
tetanusan 50% šķīdums injekcijām
kon-pharma gmbh, vācija - kalcija glikonāts, magnija hlorīda heksahidrāts, kalcija glicerofosfāts - šķīdums injekcijām - cūkas; liellopi; zirgi
lv calmasol-440 šķīdums infūzijām
sia "vetmarket", latvija - kalcija glikonāts, magnija hlorīda heksahidrāts, borskābes - šķīdums infūzijām - aitas; cūkas; liellopi
lv calmasol-204 s šķīdums injekcijām
interchemie werken de adelaar eesti as, igaunija - kalcija glikonāts,magnija hlorīda heksahidrāts,toldimfos nātrija - šķīdums injekcijām - aitas; cūkas; kaķi; liellopi; suņi; zirgi
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubicīna hidrohlorīds - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiski līdzekļi - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).